Location of Repository

Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs

By Sabine H. van Rijt and P. J. Sadler

Abstract

This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy

Topics: RC0254
Publisher: Elsevier Ltd.
Year: 2009
OAI identifier: oai:wrap.warwick.ac.uk:3367

Suggested articles

Preview

Citations

  1. (2004). A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. doi
  2. (2006). A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. doi
  3. (2007). A potent cytotoxic photoactivated platinum complex. doi
  4. (2003). A rhodium(III) complex for high-affinity DNA basepair mismatch recognition. doi
  5. (2008). Alkyne hexacarbonyl dicobalt complexes in medicinal chemistry and drug development. doi
  6. (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. doi
  7. (2006). Anticancer cyclometalated [AuIIIm(C~N~C)mL]n+ compounds: synthesis and cytotoxic properties. doi
  8. (2005). Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. doi
  9. (2007). Basis for design and development of platinum(IV) anticancer complexes. doi
  10. (2008). Catalytic organometallic anticancer complexes. doi
  11. (2005). Cellular processing of platinum anticancer drugs. doi
  12. (2004). Current clinical and preclinical photosensitizers for use in photodynamic therapy. doi
  13. (2008). Current status and future prospects for satraplatin, an oral platinum analogue. doi
  14. (2006). Design of targeting ligands in medicinal inorganic chemistry. doi
  15. (2006). Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs. doi
  16. (2008). DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. doi
  17. (2009). DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors. doi
  18. (2005). Electronic structures and SARs of the isomeric complexes alpha -, beta -, gamma - [Ru(mazpy)2Cl2] with different antitumor activities. doi
  19. (2009). Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells. doi
  20. (2007). Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. doi
  21. (2006). Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. doi
  22. (2004). Gallium in cancer treatment. doi
  23. (1999). Gold-based therapeutic agents. doi
  24. (2003). Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. doi
  25. (2007). Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. doi
  26. (2009). High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. doi
  27. (2003). Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. doi
  28. (2002). In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. doi
  29. (2003). Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. doi
  30. (2008). Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. doi
  31. (2007). Insertion of a bulky rhodium complex into a DNA cytosine-cytosine mismatch: An NMR solution study. doi
  32. (2003). Kinetics of aquation and anation of Ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. doi
  33. (2005). KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development- an overview. doi
  34. (2005). Lanthanides as anticancer agents. doi
  35. (2006). Light-activated destruction of cancer cell nuclei by platinum diazide complexes. doi
  36. (2005). Medicinal inorganic chemistry. doi
  37. (2008). Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. doi
  38. (2008). Metal and ligand control of sulfenate reactivity: arene ruthenium thiolato-mono-S-oxides. doi
  39. (2007). Metal based drugs: from serendipity to design. doi
  40. (2007). Metal-Based Therapeutics. doi
  41. (2008). Metallo-nucleosides: synthesis and biological evaluation of hexacarbonyl dicobalt 5-alkynyl-2'-deoxyuridines. doi
  42. (2004). Metals and metal compounds in cancer treatment. doi
  43. Metals in medicine. (2007) In Biological inorganic chemistry: structure and reactivity
  44. (2005). Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. doi
  45. (2008). Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. doi
  46. (2007). Non platinum metal complexes as anti-cancer drugs. doi
  47. (1999). Non-platinum chemotherapeutic metallopharmaceuticals. doi
  48. (2009). Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. doi
  49. (2002). Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. doi
  50. (2008). Oxidation induced by the antioxidant glutathione (GSH). doi
  51. (2007). Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. doi
  52. (2008). Photochemotherapy: targeted activation of metal anticancer complexes. doi
  53. (1999). Photodynamic therapeutics: basic principles and clinical applications. doi
  54. (1992). Photodynamic Therapy: Basic Principles and Clinical Applications doi
  55. (1998). Photosensitization by the near-IR-absorbing photosensitizer lutetium texaphyrin: spectroscopic, in vitro and in vivo studies. doi
  56. (2009). Pre-clinical antitumour evaluation of biphosphinic palladacycle complex in human leukaemia cells. doi
  57. (2005). Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. doi
  58. (2006). Rhenium inhibitors of cathepsin doi
  59. (2007). Ruthenium complexes can target determinants of tumor malignancy. doi
  60. (2007). Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. doi
  61. (2008). Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. doi
  62. (2004). Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. doi
  63. (2007). Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. doi
  64. (2009). Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains. doi
  65. (2004). Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. doi
  66. (2007). Targeting the mitochondrial cell death pathway with gold compounds. doi
  67. (2007). The resurgence of platinum-based cancer chemotherapy. doi
  68. (2008). The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. doi
  69. (2009). Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. doi
  70. (2007). Thioredoxin signaling as a target for cancer therapy. doi
  71. (2007). Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. doi
  72. (2006). Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. doi
  73. (2006). Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. doi
  74. (1985). X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2{d(pGpG)}]. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.